Keros Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2018 | — | $-7.2M | $23.4M |
| FY2019 | — | $-19.4M | $7.0M |
| FY2020 | — | $261.7M | $265.9M |
| FY2021 | — | $243.2M | $230.0M |
| FY2022 | — | $277.4M | $279.0M |
| FY2023 | — | $332.2M | $331.1M |
| FY2024 | — | $571.6M | $559.9M |
| FY2025 | — | $303.1M | $287.4M |